Showing 2642 results
- Media Release /
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
Regulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed… - Story /
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
Pagination
- ‹ Previous page
- 1
- …
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- …
- 265
- › Next page